RU2010149302A - Heteroarylbenzamide derivatives for use as GLK activators in the treatment of diabetes - Google Patents

Heteroarylbenzamide derivatives for use as GLK activators in the treatment of diabetes Download PDF

Info

Publication number
RU2010149302A
RU2010149302A RU2010149302/04A RU2010149302A RU2010149302A RU 2010149302 A RU2010149302 A RU 2010149302A RU 2010149302/04 A RU2010149302/04 A RU 2010149302/04A RU 2010149302 A RU2010149302 A RU 2010149302A RU 2010149302 A RU2010149302 A RU 2010149302A
Authority
RU
Russia
Prior art keywords
diabetes
treatment
oxy
compound according
heteroarylbenzamide
Prior art date
Application number
RU2010149302/04A
Other languages
Russian (ru)
Inventor
Даррен МАККЕРРЕЧЕР (GB)
Даррен Маккерречер
Курт Гордон ПАЙК (GB)
Курт Гордон Пайк
Майкл Джеймс УОРИНГ (GB)
Майкл Джеймс УОРИНГ
Original Assignee
Астразенека Аб (Se)
Астразенека Аб
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0514173A external-priority patent/GB0514173D0/en
Priority claimed from GB0516297A external-priority patent/GB0516297D0/en
Priority claimed from GB0524589A external-priority patent/GB0524589D0/en
Application filed by Астразенека Аб (Se), Астразенека Аб filed Critical Астразенека Аб (Se)
Publication of RU2010149302A publication Critical patent/RU2010149302A/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

1. Соединение 3-{[5-(азетидин-1-илкарбонил)пиразин-2-ил]окси}-5-{[(1S)-2-гидрокси-1-метилэтил]окси}-N-(5-метилпиразин-2-ил)бензамид или его фармацевтически приемлемая соль. ! 2. Соединение по п.1, представляющее собой 3-{[5-(азетидин-1-илкарбонил)пиразин-2-ил]окси}-5-{[(1S)-2-гидрокси-1-метилэтил]окси}-N-(5-метилпиразин-2-ил)бензамид. ! 3. Фармацевтическая композиция для лечения диабета 2-го типа или ожирения, содержащая соединение по п.1 или 2 вместе с фармацевтически приемлемым разбавителем или носителем. ! 4. Соединение по п.1 или 2 для применения в лечении диабета 2-го типа. ! 5. Соединение по п.1 или 2 для применения в лечении ожирения. 1. Compound 3 - {[5- (azetidin-1-ylcarbonyl) pyrazin-2-yl] oxy} -5 - {[(1S) -2-hydroxy-1-methylethyl] oxy} -N- (5-methylpyrazine -2-yl) benzamide or a pharmaceutically acceptable salt thereof. ! 2. The compound according to claim 1, which is 3 - {[5- (azetidin-1-ylcarbonyl) pyrazin-2-yl] oxy} -5 - {[((1S) -2-hydroxy-1-methylethyl] oxy} -N- (5-methylpyrazin-2-yl) benzamide. ! 3. A pharmaceutical composition for treating type 2 diabetes or obesity, comprising a compound according to claim 1 or 2 together with a pharmaceutically acceptable diluent or carrier. ! 4. The compound according to claim 1 or 2 for use in the treatment of type 2 diabetes. ! 5. The compound according to claim 1 or 2 for use in the treatment of obesity.

Claims (5)

1. Соединение 3-{[5-(азетидин-1-илкарбонил)пиразин-2-ил]окси}-5-{[(1S)-2-гидрокси-1-метилэтил]окси}-N-(5-метилпиразин-2-ил)бензамид или его фармацевтически приемлемая соль.1. Compound 3 - {[5- (azetidin-1-ylcarbonyl) pyrazin-2-yl] oxy} -5 - {[(1S) -2-hydroxy-1-methylethyl] oxy} -N- (5-methylpyrazine -2-yl) benzamide or a pharmaceutically acceptable salt thereof. 2. Соединение по п.1, представляющее собой 3-{[5-(азетидин-1-илкарбонил)пиразин-2-ил]окси}-5-{[(1S)-2-гидрокси-1-метилэтил]окси}-N-(5-метилпиразин-2-ил)бензамид.2. The compound according to claim 1, which is 3 - {[5- (azetidin-1-ylcarbonyl) pyrazin-2-yl] oxy} -5 - {[((1S) -2-hydroxy-1-methylethyl] oxy} -N- (5-methylpyrazin-2-yl) benzamide. 3. Фармацевтическая композиция для лечения диабета 2-го типа или ожирения, содержащая соединение по п.1 или 2 вместе с фармацевтически приемлемым разбавителем или носителем.3. A pharmaceutical composition for treating type 2 diabetes or obesity, comprising a compound according to claim 1 or 2 together with a pharmaceutically acceptable diluent or carrier. 4. Соединение по п.1 или 2 для применения в лечении диабета 2-го типа.4. The compound according to claim 1 or 2 for use in the treatment of type 2 diabetes. 5. Соединение по п.1 или 2 для применения в лечении ожирения. 5. The compound according to claim 1 or 2 for use in the treatment of obesity.
RU2010149302/04A 2005-07-09 2010-12-03 Heteroarylbenzamide derivatives for use as GLK activators in the treatment of diabetes RU2010149302A (en)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
GB0514173.4 2005-07-09
GB0514173A GB0514173D0 (en) 2005-07-09 2005-07-09 Chemical compounds
GB0516297.9 2005-08-09
GB0516297A GB0516297D0 (en) 2005-08-09 2005-08-09 Chemical compounds
GB0523862.1 2005-11-24
GB0524589.9 2005-12-02
GB0524589A GB0524589D0 (en) 2005-12-02 2005-12-02 Chemical compounds
GB0607977.6 2006-04-22

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2008101927/04A Division RU2415141C2 (en) 2005-07-09 2006-07-03 Heteroarylbenzamide derivatives applied as glk activators in diabetes treatment

Publications (1)

Publication Number Publication Date
RU2010149302A true RU2010149302A (en) 2012-06-10

Family

ID=41150447

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2008101927/04A RU2415141C2 (en) 2005-07-09 2006-07-03 Heteroarylbenzamide derivatives applied as glk activators in diabetes treatment
RU2010149302/04A RU2010149302A (en) 2005-07-09 2010-12-03 Heteroarylbenzamide derivatives for use as GLK activators in the treatment of diabetes

Family Applications Before (1)

Application Number Title Priority Date Filing Date
RU2008101927/04A RU2415141C2 (en) 2005-07-09 2006-07-03 Heteroarylbenzamide derivatives applied as glk activators in diabetes treatment

Country Status (1)

Country Link
RU (2) RU2415141C2 (en)

Also Published As

Publication number Publication date
RU2008101927A (en) 2009-08-20
RU2415141C2 (en) 2011-03-27

Similar Documents

Publication Publication Date Title
MY147749A (en) Heteroaryl benzamide derivatives for use as glk activators in the treatment of diabetes
WO2007007042A8 (en) Heteroaryl benzamide derivatives for use as glk activators in the treatment of diabetes
TW200714597A (en) Chemical compounds
AR064735A1 (en) GPCR AGONISTS AND PHARMACEUTICAL COMPOSITION BASED ON THE COMPOUND
PE20091842A1 (en) PYRROLIDINONES AS GLUCOKINASE ACTIVATORS
DE602005023343D1 (en) Pyrimidine derivatives as GPCR-agonists
PE20130242A1 (en) DERIVATIVES OF ISOXAZOLO-PYRIDINE
MX2008000255A (en) Urea glucokinase activators.
PE20080677A1 (en) PYRROLOTRIAZINE INHIBITORS CINAZA
JP2009215321A5 (en)
PE20070585A1 (en) SULFONAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS
ATE496622T1 (en) USE OF THIENOPYRIDONE DERIVATIVES AS AMPK ACTIVATORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
NO20083514L (en) Heterobicyclic sulfonamide derivatives for the treatment of diabetes
EA201000562A1 (en) DERIVATIVES N- (PYRAZOL-3-IL) BENZAMIDE AS ACTIVATORS GLUKOKINAZES
ATE432259T1 (en) PYRIDINE DERIVATIVES AS DIPEPTEDYL PEPTIDASE INHIBITORS
MX2009004467A (en) Benzoyl amino heterocyclyl compounds as glucokinase (glk) activators.
PE20091527A1 (en) PYRIDAZINONE DERIVATIVES
RS51174B (en) Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood glp-1 level
ATE517874T1 (en) PYRIMIDINONES AS MODULATORS OF CASEINKINASE II (CK2)
PE20120632A1 (en) BACE INHIBITORS
EA200702363A1 (en) NEW HISTAMINE H-RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS
MX2007006284A (en) Biaryloxymethylarene carboxylic acids.
DE602007009420D1 (en) OXADIAZOL DERIVATIVES AS S1P1 RECEPTOR AGONISTS
SG163610A1 (en) Macrocyclic inhibitors of hepatitis c virus
TW200745004A (en) Novel compounds, their preparation and use

Legal Events

Date Code Title Description
FA93 Acknowledgement of application withdrawn (no request for examination)

Effective date: 20131204